Truist Securities Reiterates Buy on Kymera Therapeutics, Raises Price Target to $150

Benzinga · 22h ago
Truist Securities analyst Srikripa Devarakonda reiterates Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $136 to $150.